US Army Advanced Education Program in Periodontics, Ft. Gordon, GA, USA.
J Clin Periodontol. 2010 Apr;37(4):390-7. doi: 10.1111/j.1600-051X.2010.01546.x.
To evaluate the injectability, biocompatibility, safety, and periodontal wound healing/regeneration following application of a novel bioresorbable recombinant human growth/differentiation factor-5 (rhGDF-5)/poly(lactic-co-glycolic acid) (PLGA) construct.
Periodontal pockets (3 x 6 mm, width x depth) were surgically created over the buccal roots of the second and fourth mandibular pre-molars in eight adult Hound Labrador mongrel dogs. Surgeries including injection of the rhGDF-5/PLGA construct into the pockets were sequenced that four animals provided 2-/4-week and four animals 6-/8-week observations of sites receiving rhGDF-5/PLGA or serving as sham-surgery control.
The rhGDF-5/PLGA construct was easy to prepare and apply. Approximately 0.2 ml (93 microg rhGDF-5)/tooth was used. Clinical and radiographic healing was exemplary without adverse events. Healing was characterized by a non-specific connective tissue attachment, acellular/cellular cementum, periodontal ligament (PDL), bone regeneration, and a junctional epithelium. PLGA fragments were observed in 4/7, 2/8, and 1/8 sites at 2, 4, and 6 weeks, respectively. Associated inflammatory reactions exhibited no limiting effect on periodontal wound healing/regeneration. Root resorption/ankylosis was not observed. Bone formation showed apparent increased maturity (lamellar bone) at 6 weeks in sites receiving rhGDF-5/PLGA compared with the control. Both protocols exhibited significant increases in PDL, cementum, and bone regeneration over time, without significant differences between treatments. In time, PDL and cementum regeneration was twofold greater for the control at 4 weeks (p=0.04) while increased bone formation was observed at sites receiving rhGDF-5/PLGA (p<0.01).
In conclusion, the rhGDF-5/PLGA construct appears to be a safe technology for injectable, ease-of-use application of rhGDF-5-stimulated periodontal wound healing/regeneration. Additional work to optimize the polymer carrier and rhGDF-5 release kinetics/dose might be required before evaluating the efficacy of this technology in clinical settings using minimally invasive approaches.
评估新型可生物降解重组人生长/分化因子-5(rhGDF-5)/聚乳酸-共-乙醇酸(PLGA)构建物的可注射性、生物相容性、安全性以及牙周伤口愈合/再生情况。
在 8 只成年猎犬杂种犬的第二和第四下颌前磨牙颊侧根上通过手术形成牙周袋(3x6mm,宽 x 深)。手术包括将 rhGDF-5/PLGA 构建物注入袋中,其中 4 只动物分别在 2 周和 4 周以及 6 周和 8 周观察接受 rhGDF-5/PLGA 的部位或作为假手术对照的部位。
rhGDF-5/PLGA 构建物易于制备和应用。每颗牙使用约 0.2ml(93μg rhGDF-5)。临床和放射学愈合良好,无不良事件。愈合特征为非特异性结缔组织附着、无细胞/细胞状牙骨质、牙周韧带(PDL)、骨再生和结合上皮。在第 2、4 和 6 周时,分别在 4/7、2/8 和 1/8 个部位观察到 PLGA 片段。相关炎症反应对牙周伤口愈合/再生没有限制作用。未观察到牙根吸收/粘连。与对照组相比,在接受 rhGDF-5/PLGA 的部位,6 周时骨形成表现出明显增加的成熟度(板层骨)。两种方案均随着时间的推移显示出 PDL、牙骨质和骨再生的显著增加,且两种治疗方法之间无显著差异。随着时间的推移,4 周时对照组的 PDL 和牙骨质再生增加了两倍(p=0.04),而在接受 rhGDF-5/PLGA 的部位观察到骨形成增加(p<0.01)。
综上所述,rhGDF-5/PLGA 构建物似乎是一种安全的技术,可用于注射使用 rhGDF-5 刺激的牙周伤口愈合/再生。在使用微创方法评估该技术在临床环境中的疗效之前,可能需要进一步优化聚合物载体和 rhGDF-5 释放动力学/剂量。